Thousand Oaks, CA (June 4)–Amgen agreed to acquire Ilypsa (Santa Clara, CA), a private company that develops nonabsorbed drugs for renal disorders, for $420 million. The acquisition
includes Ilypsa's ILY101 drug candidate, a late-stage selective phosphate binder that treats hyperphosphatemia in chronic
kidney disease (CKD) patients. Amgen also will gain Ilypsa's proprietary, high-throughput, discovery and development platform.
Under the terms of the agreement, Amgen will purchase Ilypsa for $420 million in cash, and Ilypsa will become a wholly-owned
subsidiary of Amgen when the transaction is completed. Ilypsa's shareholders and both companies' boards of directors approved
the acquisition. The deal is subject to customary closing conditions and regulatory approvals and is expected to close in
the third quarter of 2007.
ILY101 is an orally administered, nonabsorbed polymeric agent that blocks the absorption of ingested phosphate. Studies suggest
that ILY101 may heighten phosphate-binding selectivity and capacity compared with currently available polymeric phosphate-binding
agents. ILY101 has completed Phase II trials in patients with CKD who are on hemodialysis. Amgen believes the agent is a strategic
fit for its portfolio of nephrology drugs.
Thousand Oaks, CA (June 6)–Amgen agreed to acquire Alantos (Cambridge, MA), a privately held company developing treatments for diabetes and inflammatory disease for $300 million. Alantos'
lead drug candidate, ALS 2-0426, is a DPP-IV inhibitor in clinical development (Phase IIa) for the treatment of Type 2 diabetes.
The deal is expected to close in the third quarter of 2007.
London (June 4)–AstraZeneca AstraZeneca acquired a biologics manufacturing facility in Montreal, Canada from DSM Biologics, Inc. (Heerleen, Netherlands). The 66,000 ft2 facility will be used to manufacture antibody drug candidates for clinical trials. Work will start to recommission the facility,
and AstraZeneca plans to commence full-scale production in 2009.
In December 2005, DSM mothballed the Montreal facility as part of its strategy for DSM Biologics to focus on the development
and out-licensing of a new manufacturing technology platform based on the "PER.C6" human cell line, in a joint venture with
the Dutch biotechnology company Crucell N.V.
London (June 6)–AstraZeneca completed its tender offer for all outstanding shares of MedImmune, Inc. (Gaithersburg, MD) AstraZeneca purchased nearly 220,000,000 shares, which represent approximately 91.6% of MedImmune's outstanding
shares. AstraZeneca plans to effect a short-form merger on or about June 18, 2007 to complete the acquisition.
Aliso Viejo, CA (June 5)–Valeant Pharmaceuticals International will sell its manufacturing facilities in Humacao, Puerto Rico and Basel, Switzerland to Legacy Pharmaceuticals International.
The sale includes the divestiture of Valeant's product "Reptilase." Terms of the agreement were not disclosed.
Utter Pradesh, India (June 1)–Jubilant Organosys Ltd. completed its acquisition of Hollister-Stier Laboratories (Spokane, WA). The total purchase price was $122 million.
Cambridge, MA (May 30)–Genzyme agreed to buy its US partner Bioenvision (New York) in an all-cash transaction.The acquisition's total value is approximately $345 million. Genzyme is pursuing the
deal to gain exclusive rights to clofarabine, a cancer drug the companies developed together.
Genzyme markets clofarabine as "Clolar" in the United States and Canada to treat relapsed and refractory pediatric acute lymphoblastic
leukemia (ALL) patients. The United States and the European Union granted clofarabine orphan-drug status for ALL and acute
myeloid leukemia (AML). Genzyme seeks to expand clofarabine's use into adult populations, especially to treat AML.
Bioenvision markets clofarabine in Europe and also markets "Modrenal" (trilostane), a postmenopausal breast-cancer drug approved
in the United Kingdom.
San Carlos, CA (May 24)–Nektar Therapeutics announced a restructuring plan aimed at reducing its ongoing spending. The company will cut 25% of its staff and reduce
its spending by approximately $65 million. Nektar hopes the restructuring will allow it to accelerate the development of its